Abstract: Sulfonylurea receptor nucleic acid and amino acid sequences are disclosed. The invention is also directed to expression vectors comprising the nucleic acid sequences and to isolated host cells that express the nucleic acid sequences.

Abstract: The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, mice which are heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such deficiency. The present invention further provides the use of any of the above mice and cell lines in situations where the absence of at least one RAR or RXR receptor(s), or the normal expression thereof, is desirable.

Abstract: Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.

Abstract: The present invention relates to methods and reagents for drug and pesticide screening. Screening methods are disclosed employing normal and mutant receptors, allowing for the testing of large numbers of potentially useful compounds.

Abstract: Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen dramatically downregulates SR-BI under conditions of tremendous upregulation of the LDL-receptor. The examples also demonstrate the upregulation of SR-BI in rat adrenal membranes and other non-placental steroidogenic tissues from animals treated with estrogen, but not in other non-placental non-steroidogenic tissues, including lung, liver, and skin. Examples further demonstrate the uptake of fluorescently labeled HDL into the liver cells of animal, which does not occur when the animals are treated with estrogen. Examples also demonstrate the in vivo effects of SR-BI expression on HDL metabolism, in mice transiently overexpressing hepatic SR-BI following recombinant adenovirus infection. Overexpression of the SR-BI in the hepatic tissue caused a dramatic decrease in cholesterol blood levels.

Abstract: This invention relates to novel mammalian excitatory amino acid transporter proteins and genes encoding such proteins. The invention is directed towards the isolation, characterization and use of human excitatory amino acid transporter proteins for pharmacological screening of analogues, agonists, antagonists, inhibitors, modulators and facilitators of excitatory amino acid transport in a variety of tissues, particularly neuronal tissues. This invention provides isolated nucleic acid encoding a novel excitatory amino acid transporter subtype that is specifically expressed in retina. Also provided are recombinant expression constructs capable of expressing this novel transporter in transformed prokaryotic and eukaryotic cells, and also provides such transformed cell cultures producing the novel human transporter. Purified transporter protein and membranes comprising the transporter protein are also provided.

Abstract: The present invention provides a human transmembrane protein (ONMO) and polynucleotides which identify and encode ONMO. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing ONMO and for treating or preventing disorders associated with expression of ONMO.

Abstract: Cell lines that stably incorporate human D.sub.4 receptor-encoding DNA are provided which are particularly useful in procedures for screening compounds for potential anti-psychotic activity.

Abstract: Oligonucleotide sequences are provided coding for T-cell-specific antigen receptors or fragments thereof. The oligonucleotide sequences can be used as probes for detecting helper and cytotoxic T-cells, preparing and isolating DNA sequences encoding for the receptor polypeptide, and in constructions for expression of receptor polypeptides or fragments thereof. In addition, processing signals from the receptor subunits can be employed in conjunction with modified wild type oligonucleotide sequences or non-wild type oligonucleotide sequences.

Abstract: A recombinant human IL-12 beta2 receptor protein produced on the surface of a non-human mammalian cell, free from other human proteins, in its active form. In addition, a non-human mammalian cell having expressed on its surface the recombinant human IL-12 beta2 receptor protein, which cell proliferates in the presence of human IL-12. A non-human mammalian cell having the human IL-12 beta2 receptor protein on its surface and which proliferates in response to human IL-12 is useful for determining whether a given compound inhibits biological activity of human IL-12 or is an IL-12 agonist.

Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

Abstract: The invention provides substantially purified T-cadherin polypeptides and isolated nucleic acids which encode the T-cadherin polypeptides. Antibodies reactive with various forms of T-cadherin, but not reactive with N-, E- or P-cadherin are also provided. The invention provides methods for detecting the various forms of T-cadherin in a subject as well as a method of detecting tumor growth which consists of inhibiting the activity of T-cadherin in a tumor. A method of effecting traumatized neurons is provided. The method entails treating traumatized neurons with a therapeutically effective dose of T-cadherin.

Abstract: A gene is provided which is present in the deletion region of a chromosome common in lung cancer, hepatocellular carcinoma and colorectal cancer and encodes a novel protein, a protein encoded by the gene (PRLTS protein), and a method of discriminating tumor cells. With respect to the human chromosome 8, a detailed gene map was prepared, the chromosome of each of lung cancer, hepatocellular carcinoma and colorectal cancer tissues was analyzed, and a gene encoding a novel protein was cloned to thereby determine the structure thereof. A gene analysis was conducted with the use of a DNA probe derived from the above gene, and consequently mutations in the gene were confirmed in the lung cancer, hepatocellular carcinoma and colorectal cancer tissues.

Abstract: The invention provides CTLA4 mutant molecules as ligands for the B7 antigen. Methods are provided for expressing CTLA4 mutant molecules as soluble, functional molecules, for preparing CTLA4 mutant fusion proteins, and for using these soluble molecules to regulate T cell interactions and immune responses mediated by such interactions.

Abstract: A DNA sequence encoding a novel human growth factor receptor referred to as a type III receptor tyrosine kinase is described. The amino acid sequence of the receptor is also described. The receptor has a sequence which is similar to that of the kinase domains of known type III receptor tyrosine kinases, but which is unique in its kinase insert domain sequence. The receptor binds specifically to the vascular endothelial cell growth factor.

Abstract: A method of determining the ability of a compound to both bind to somatostatin type-5 receptor ("SSTR-5") and inhibit amylin release. The method includes obtaining a preparation, either a cell preparation or a membrane preparation, which contains SSTR-5; incubating the preparation, the compound, and a SSTR-5 ligand, at least one of the ligand and the compound being detectably labeled; determining the ability of the compound to compete against the ligand for binding to SSTR-5; if and only if the compound is determined to be able to bind to SSTR-5, obtaining pancreatic cells; incubating the compound, the pancreatic cells, and an amylin release stimulator under conditions in which the amylin release stimulator would induce release of amylin from the pancreatic cells; and determining the ability of the compound to inhibit amylin release. Also disclosed is a method of treating hyper-amylinemia with a ligand selective for SSTR-5.

Abstract: The invention provides an isolated cDNA sequence coding for murine interleukin 5 receptor, murine secretory interleukin 5 receptor, human interleukin 5 receptor, and human secretory interleukin 5 receptor and products including murine interleukin 5 receptor, murine secretory interleukin 5 receptor, and human interleukin 5 receptor which are produced using the isolated cDNA sequence. These products may be useful for a therapeutic agent for autoimmune disorders and diseases with eosinophilia in which human IL-5 is believed to be involved.

Abstract: Disclosed are (1) a water-soluble mutein of an animal protein having activity as a receptor for a fibroblast growth factor (FGF) protein, (2) a recombinant DNA having a nucleotide sequence coding for the above water-soluble mutein, (3) a vector containing the above recombinant DNA, (4) a transformant transformed with the above vector, and (5) a process for producing the water-soluble mutein which comprises cultivating the above transformant in a culture medium, the mutein being useful as therapeutic agents or to enhance cell proliferation activity.

Abstract: The invention relates to the human alpha interferon receptor and to the DNA sequence, including the cDNA sequence, encoding the receptor. The invention also relates to non-human cells which express said receptor, to a process for obtaining said cells, and to a process for the preparation of the receptor.

Abstract: The present invention relates to novel process for the preparation of glycoproteins by mammalian cell culture wherein the sialic acid content of the glycoprotein produced is controlled over a broad range of values by manipulating the cell culture environment. The invention provides for processes in which the sialic acid content of the glycoprotein is modified by changes in cell culture parameters which affect cell specific productivity. Preferred embodiments of the invention include cell culture processes in the osmolality of the cell culture is controlled as well as the concentration of a transcription enhancer during the production phase of the cell culture. The invention further provides for novel preparations of soluble type 1 tumor necrosis factor immunoglobulin G1 and their uses in the treatment of inflammatory or immune related disorders.

Abstract: The invention provides soluble forms of the Fas (Apo-1 ) protein comprising both the intracellular and extracellular domains of the full-length polypeptide. Exemplified is a naturally-occurring splice variant of the Fas gene, Fas.DELTA.TM, which lacks the transmembrane domain of the native antigen. DNA encoding the protein, cells expressing the recombinant DNA, and methods of using the protein and DNA are also provided.

Abstract: The present invention provides an isolated nucleic acid molecule encoding an 5-HT.sub.2 receptor, and an isolated protein which is a human 5-HT.sub.2 receptor.The invention also provides vectors comprising DNA molecules encoding a human 5-HT.sub.2 receptor, and vectors adapted for expression of the 5-HT.sub.2 receptor in bacterial, yeast, or mammalian cells.In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the 5-HT.sub.2 receptor, a method for determining whether a ligand which is not known to be capable of binding to the 5-HT.sub.2 receptor can bind to the 5-HT.sub.2 receptor, a method for detecting the presence of 5-HT.sub.2 receptor on the surface of a cell, and a method of screening drugs to identify drugs which specifically interact with, and bind to, the 5-HT.sub.2 receptor.The invention herein also concerns an antibody directed to the human 5-HT.sub.2 receptor, such as a monoclonal antibody directed to an epitope of the 5-HT.sub.

Abstract: The present invention relates to novel mammalian amino acid transporter proteins and the genes that encode such proteins. The invention is directed toward the isolation, characterization and pharmacological use of the human amino acid transporter proteins EAAT1, EAAT2, EAAT3 and ASCT1. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to each of these transporter genes. Also provided are recombinant expression constructs capable of expressing each of the amino acid transporter genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the human amino acid transporter proteins encoded therein. The invention also provides methods for screening in vitro compounds having transport-modulating properties using preparations of transporter proteins from such cultures of cells transformed with recombinant expression constructs.

Abstract: The present invention relates to a novel mammalian methadone-specific opioid receptor protein and genes that encode a such protein. The invention is directed toward the isolation, characterization and pharmacological use of mammalian methadone-specific opioid receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to the rat homologue or the mammalian methadone-specific opioid receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian methadone-specific opioid receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian methadone-specific opioid receptor proteins encoded therein.

Abstract: Nucleotidic sequences coding for the bovine adrenergic-.beta..sub.3 receiver (RA.beta..sub.3), utilization of said sequences as probes and for the expression of peptides and/or fragments thereof having an activity of bovine RA.beta..sub.3, vectors useful for said expression, as well as cellular hosts containing said vector. Polyclonal and monoclonal antibodies raised against said peptides and usable, particularly for the detection of bovine adrenergic-.beta..sub.3 receivers, as well as method for screening substances, with agonist or antagonist action in relation to peptides having an adrenergic-.beta..sub.3 receiver activity and kits for the detection of the affinity degrees of different substances for said peptides having an adrenergic-.beta..sub.3 receiver activity. Transgenic and recombinant mice containing said nucleotidic sequence.

Abstract: Described herein are isolated polynucleotides which code for an AMPA-type human CNS receptor, designated the human GluR4B receptor. The receptor is characterized structurally and the construction and use of cell lines expressing the receptor is disclosed.

Abstract: The present invention provides a novel .beta.1.fwdarw.6 N-acetylglucosaminyltransferase, which forms core 2 oligosaccharide structures in O-glycans, and a novel acceptor molecule, leukosialin, CD43, for core 2 .beta.1.fwdarw.6 N-acetylglucosaminyltransferase activity. The amino acid sequences and nucleic acid sequences encoding these molecules, as well as active fragments thereof, also are disclosed. A method for isolating nucleic acid sequences encoding proteins having enzymatic activity is disclosed, using CHO cells that support replication of plasmid vectors having a polyoma virus origin of replication. A method to obtain a suitable cell line that expresses an acceptor molecule also is disclosed.

Abstract: The subject invention provides purified polypeptides encoded by naturally-occurring wild-type platelet glycoprotein Ib alpha having a mutation which renders the polypeptide more reactive with yon Willebrand factor. Preferably, the mutation is in the hinge region of GP Ib.alpha., such as the substitution of valine for glycine at residue 233. These mutations alter the three-dimensional structure of the mutant polypeptide from a beta bend conformation to an alpha helix formation, and also create an amphipathic region within the mutant polypeptide. DNA encoding the mutant polypeptides, as well as expression systems for the production of the mutant polypeptides, are also provided. Methods and compositions using the mutant polypeptides and DNA oligomers complementary to the mutant polypeptides are further provided.

Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors, of the kainate binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein described are recombinant cell lines which produce the EAA receptor as a heterologous membrane-bound product. Also described are related aspects of the invention, which are of commercial significance. Included is use of the cell lines as a tool for discovery of compounds which modulate EAA receptor stimulation.

Abstract: The present invention provides a bovine group I phospholipase A.sub.2 receptor comprising an amino acid sequence from Leu in the 486 position to Pro in the 940 position of SEQ ID No. 1, and a gene encoding the bovine group I phospholipase A.sub.2 receptor. It was found that the bovine group I phospholipase A.sub.2 receptor has multi-domain structure.

Abstract: A novel receptor-type protein tyrosine phosphatase-.beta. (RPTP.beta.) protein or glycoprotein, and the DNA coding therefor is disclosed. This protein is naturally expressed in the brain and in neural cell lines. The RPTP.beta. protein or glycoprotein may be produced by recombinant means. Antibodies to the protein, methods for measuring the quantity of the protein, methods for screening compounds, such as drugs, which can bind to the protein and inhibit or stimulate it phosphatase enzymatic activity, are provided.

Abstract: Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.